-
公开(公告)号：US20210145759A1
公开(公告)日：2021-05-20
申请号：US17045127
申请日：2019-03-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Lauren Emily Barney , Michael Beauregard , Guillaume Carmona , Francisco Caballero Gonzalez , Richard Heidebrecht , Erika Ellen Johnston , Robert James Miller , Matthias Alexander Oberli , Owen O'Connor , David Peritt , Jared A. Sewell , Devyn McKinley Smith , Omid Veiseh , Paul Kevin Wotton
Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
-
公开(公告)号：US20200263196A1
公开(公告)日：2020-08-20
申请号：US16651892
申请日：2018-09-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Guillaume Carmona , Francisco Caballero Gonzalez , Richard Heidebrecht , Robert James Miller , Matthias Alexander Oberli , David Peritt , Jared A. Sewell , Devyn McKinley Smith , Omid Veiseh , Paul Kevin Wotton
IPC: C12N15/85 , C12N5/079 , A61K35/30 , C07K14/755 , C07K14/55 , C07K14/635 , A61K9/00 , A61K9/48 , A61K47/54
Abstract: Described herein are cell compositions comprising an active cell (e.g., an engineered active cell, e.g., an engineered RPE cell) or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an active cell, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
-
公开(公告)号：US12161760B2
公开(公告)日：2024-12-10
申请号：US17045127
申请日：2019-03-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Lauren Emily Barney , Michael Beauregard , Guillaume Carmona , Francisco Caballero Gonzalez , Richard Heidebrecht , Erika Ellen Johnston , Robert James Miller , Matthias Alexander Oberli , Owen O'Connor , David Peritt , Jared A. Sewell , Devyn McKinley Smith , Omid Veiseh , Paul Kevin Wotton
Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
-
公开(公告)号：US20230123802A1
公开(公告)日：2023-04-20
申请号：US17598154
申请日：2020-03-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Lauren Emily Barney , Michael Beauregard , Guillaume Carmona , Francisco Caballero Gonzalez , Richard Heidebrecht , Erika Ellen Johnston , Robert James Miller , Owen O'Connor , Matthias Alexander Oberli , David Peritt , Jared A. Sewell , Devyn McKinley Smith , Omid Veiseh , Paul Kevin Wotton , Zoe Yin
Abstract: Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.
-
Patent Agency Ranking
公开(公告)号：US20200039943A1
公开(公告)日：2020-02-06
申请号：US16339285
申请日：2017-10-03
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Omid Veiseh , Richard Heidebrecht , Paul Kevin Wotton , Matthias Alexander Oberli , Robert James Miller
IPC: C07D249/04 , A61P37/04 , A61P37/06 , A61K9/00 , A61K35/30 , C07K16/22 , A61K39/395 , C12N9/40 , A61K38/47 , A61K31/541 , C07D405/12 , A61K31/4192 , C07D295/088 , A61K31/54 , C07H15/26 , A61K31/7056 , C07F7/18 , A61K31/695 , C07D405/14 , C07D403/12 , C07D409/04
Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
-
公开(公告)号：US20240279187A1
公开(公告)日：2024-08-22
申请号：US18529334
申请日：2023-12-05
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Omid Veiseh , Richard Heidebrecht , Paul Kevin Wotton , Matthias Alexander Oberli , Robert James Miller
IPC: C07D249/04 , A61K9/00 , A61K31/4192 , A61K31/54 , A61K31/541 , A61K31/695 , A61K31/7056 , A61K35/30 , A61K38/47 , A61K39/395 , A61P37/04 , A61P37/06 , C07D295/088 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/04 , C07F7/18 , C07H15/26 , C07K16/22 , C12N9/40
CPC classification number: C07D249/04 , A61K9/0019 , A61K31/4192 , A61K31/54 , A61K31/541 , A61K31/695 , A61K31/7056 , A61K35/30 , A61K38/47 , A61K39/3955 , A61P37/04 , A61P37/06 , C07D295/088 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/04 , C07F7/1804 , C07F7/1892 , C07H15/26 , C07K16/22 , C12N9/2465 , C12Y302/01022
Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
-
公开(公告)号：US11945786B2
公开(公告)日：2024-04-02
申请号：US16339285
申请日：2017-10-03
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Omid Veiseh , Richard Heidebrecht , Paul Kevin Wotton , Matthias Alexander Oberli , Robert James Miller
IPC: A61K31/4192 , A61K9/00 , A61K31/05 , A61K31/54 , A61K31/541 , A61K31/695 , A61K31/7056 , A61K35/30 , A61K38/47 , A61K39/395 , A61P3/00 , A61P7/02 , A61P7/04 , A61P37/00 , A61P37/04 , A61P37/06 , A61P43/00 , C07D249/04 , C07D249/06 , C07D295/088 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07F7/18 , C07H15/26 , C07K16/22 , C12N9/40
CPC classification number: C07D249/04 , A61K9/0019 , A61K31/4192 , A61K31/54 , A61K31/541 , A61K31/695 , A61K31/7056 , A61K35/30 , A61K38/47 , A61K39/3955 , A61P37/04 , A61P37/06 , C07D295/088 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/04 , C07F7/1804 , C07F7/1892 , C07H15/26 , C07K16/22 , C12N9/2465 , C12Y302/01022
Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
-
公开(公告)号：US20220267794A1
公开(公告)日：2022-08-25
申请号：US17598176
申请日：2020-03-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Lauren Emily Barney , Michael Beauregard , Guillaume Carmona , Francisco Caballero Gonzalez , Richard Heidebrecht , Erika Ellen Johnston , Robert James Miller , Owen O'Connor , Matthias Alexander Oberli , David Peritt , Jared A. Sewell , Devyn McKinley Smith , Omid Veiseh , Jeffrey Charles Way , Paul Kevin Wotton , Zoe Yin , Elina Makino , Brian Richard Fluharty , Marianthi Papakosta
Abstract: Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.
-
公开(公告)号：US20220000789A1
公开(公告)日：2022-01-06
申请号：US17280802
申请日：2019-09-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Lauren Emily Barney , Michael Beauregard , Guillaume Carmona , Francisco Caballero Gonzalez , Richard Heidebrecht , Erika Ellen Johnston , Robert James Miller , Owen O'Connor , Matthias Alexander Oberli , David Peritt , Jared A. Sewell , Devyn McKinley Smith , Omid Veiseh , Paul Kevin Wotton , Zoe Yin
Abstract: Described herein are implantable devices comprising means for mitigating the foreign body response (FBR) and at least one cell-containing compartment which comprises a plurality of cells (e.g., live cells) encapsulated in a polymer composition comprising a cell-binding substance (CBS), as well as compositions and methods of making and using the same. The cells are capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.015 seconds)
